Aerie Pharmaceuticals Logo

News Releases

Date Title View
Toggle Summary Aerie Pharmaceuticals to Participate in Upcoming Investor Conferences
DURHAM, N.C. --(BUSINESS WIRE)--Nov. 9, 2021-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and
View HTML
Toggle Summary Aerie Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update
Third Quarter 2021 Net Revenues of $29.3 Million Increased 46% over Third Quarter   2020   Third Quarter 2021 Net Revenue Per Bottle of $89 , up 16% over Third Quarter 2020 Phase 3 Studies for AR-15512 and AR-1105 Expected to Begin in the First Half of 2022 Conference Call and Webcast Today,
View HTML
Toggle Summary Aerie Pharmaceuticals to Announce Third Quarter 2021 Financial Results and Host Conference Call on Thursday, November 4, 2021
DURHAM, N.C. --(BUSINESS WIRE)--Oct. 28, 2021-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company, announced today that its third quarter 2021 financial results will be released after the market closes on Thursday, November 4, 2021 .
View HTML
Toggle Summary Aerie Pharmaceuticals Announces Presentation at the Ophthalmology Innovation Summit Glaucoma Innovation Showcase
DURHAM, N.C. --(BUSINESS WIRE)--Oct. 21, 2021-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company, today announced that Tom Mitro , President and Chief Operating Officer presented an overview on Aerie’s glaucoma franchise at the Ophthalmology Innovation Summit
View HTML
Toggle Summary Aerie Pharmaceuticals Announces Positive Phase 3 Topline Results for Netarsudil Ophthalmic Solution 0.02% Clinical Trial in Japan
Netarsudil Ophthalmic Solution 0.02% Once Daily Demonstrated Superiority to Ripasudil 0.4% Twice Daily DURHAM, N.C. --(BUSINESS WIRE)--Oct. 12, 2021-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company, today reported positive topline results for the Company’s Phase 3
View HTML
Toggle Summary Aerie Pharmaceuticals Announces Presentation at the Ophthalmology Innovation Summit Retina Innovation Showcase
DURHAM, N.C. --(BUSINESS WIRE)--Oct. 7, 2021-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company, today announced that Casey Kopczynski , Ph.D., Chief Scientific Officer presented an overview on Aerie’s retina product candidates, at the Ophthalmology Innovation Summit
View HTML
Toggle Summary Aerie Pharmaceuticals Announces Presentation at the 39th Annual Scientific Meeting of the American Society of Retina Specialists
DURHAM, N.C. --(BUSINESS WIRE)--Oct. 6, 2021-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company, today announced that topline results from the AR-1105 (dexamethasone intravitreal implant) Phase 2 clinical trial in patients with macular edema due to retinal vein
View HTML
Toggle Summary Aerie Pharmaceuticals to Participate in the Cantor Global Healthcare Conference
DURHAM, N.C. --(BUSINESS WIRE)--Sep. 27, 2021-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases
View HTML
Toggle Summary Aerie Pharmaceuticals, Inc. Announces the Appointment of Interim Executive Chair and Departure of Chairman and CEO
DURHAM, N.C. --(BUSINESS WIRE)--Sep. 21, 2021-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company, today announced that it is executing its succession plan for its long-serving Chairman and CEO and that effective September 17, 2021 , Vicente Anido , PhD.
View HTML
Toggle Summary Aerie Pharmaceuticals Announces Appointment of Erik Pacyniak, Ph.D., D.A.B.T., as Director, Toxicology and Drug Disposition
DURHAM, N.C. --(BUSINESS WIRE)--Sep. 20, 2021-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and
View HTML
TOP